Management Team

Frederick Sancilio, M.S., Ph.D.

Frederick_Sancilio

Frederick D. Sancilio, M.S., Ph.D., is our founder and has served as our Chairman, President and Chief Executive Officer since November 2006. Dr. Sancilio has over 40 years of experience in the pharmaceutical research, development, manufacturing and distribution industries. Prior to founding the Company, Dr. Sancilio founded three successful pharmaceutical companies, one of which includes aaiPharma Inc., a contract research organization. Dr. Sancilio is an experienced pharmaceutical executive, development scientist and accomplished entrepreneur. He has published over 20 articles in peer reviewed scientific journals, holds 14 domestic and international patents and has presented to scientists in conferences around the world. Over the course of his career, he has contributed to the development of over 1,000 drugs marketed in the United States, Europe and Asia. Dr. Sancilio earned a Ph.D. in Physical and Analytical Chemistry and an M.S. from Rutgers University.

Marc Wolff

Marc_Wolff

Marc Wolff joined us in January 2015 as our Executive Vice President and Chief Financial Officer. He has more than sixteen years of experience in the life sciences industry in various global finance leadership and general management roles. Prior to joining us, from October 2013 to June 2014, Mr. Wolff served as Chief Financial Officer of JHP Pharmaceuticals, LLC, or JHP, a fully integrated specialty pharmaceutical company that acquires, develops, manufactures and sells branded and generic sterile products. He left JHP following the successful completion of the merger with Par Pharmaceutical. Prior to then, from June 2013 to September 2013, Mr. Wolff served as Chief Financial Officer of Research Pharmaceutical Services, Inc. (RPS) a leading provider of disruptive and innovative outsourcing clinical development solutions present in over 60 countries worldwide. In this role, Mr. Wolff directed all financial, tax and treasury aspects of the business including accounting practices, budgeting, financial planning, financing, interface with the financial community, financial analysis, acquisitions and ventures, and monitoring financial, tax and treasury performance. He left RPS following the successful completion of the merger with PRA International. Prior to RPS, Mr. Wolff spent over fifteen years with Catalent Pharma Solutions, a global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products, where he held various global finance leadership and general management roles. In his last position at Catalent Pharma Solutions, Mr. Wolff served as Vice President Finance for the Softgel Technologies division, and Vice President and General Manager Softgel Technologies for Asia Pacific. Mr. Wolff also worked in public accounting from 1993 to 1998 at Arthur Andersen in France. He earned a Master in Management from Ecole Supérieure de Commerce de Reims, France in 1992.

Albert Cavagnaro

Albert Cavagnaro joined us in September 2015 as our Chief Legal Officer. Mr Cavagnaro has over 20 years of experience in the pharmaceutical and biotechnology industries.  Prior to joining us, from August 2011 to September 2015, Mr Cavagnaro served as General Counsel to Osmotica Pharmaceutical Corp., a specialty pharmaceutical company that develops and manufactures branded and generic pharmaceutical products.  Mr Cavagnaro also served on Osmotica’s executive committee, which was responsible for overseeing the strategic direction of all administrative and operational functions of the organization, and assisted the company in its transformation from a generic drug developer into a specialty pharmaceutical company complete with commercial manufacturing capabilities and two Phase III NDA products.  Prior to Osmotica, from May 2011 to August 2011, Mr Cavagnaro served as a consultant to start-up and mature companies in various industries assisting them in organizational, legal and strategic issues.  Prior to this, Mr Cavagnaro spent seventeen years with AAIPharma Inc. (later known as ZeeCRO Inc.), a drug development and manufacturing service provider, where he worked in positions of increasing responsibility and most recently as Vice President, Corporate Legal Affairs.  Mr Cavagnaro earned an AB in Mathematics from Duke University and an MBA and JD from the University of North Carolina.

Adrian L. Rabinowicz, M.D., FAAN

Adrian Rabinowicz

Adrian L. Rabinowicz, M.D., FAAN, joined Sancilio Pharmaceuticals Company, Inc. (SPCI)
as Chief Medical Officer in April 2016. Dr. Rabinowicz will have responsibility for SPCI’s clinical development, clinical strategy and operational activities to advance the company’s pipeline.

Before joining Sancilio Pharmaceuticals, Dr. Rabinowicz spent over 18 years in different global pharmaceutical and biotechnology companies, holding roles of increasing responsibility covering clinical development and medical affairs in a variety of therapeutic areas and was involved in numerous NDA submissions. Most recently, Dr. Rabinowicz was Senior Vice President Clinical Development and Medical Affairs at Acorda Therapeutics, a publicly traded company, and was responsible for helping progress their late stage CNS programs and preparing the medical affairs department to support future product launches, while also interacting with regulatory authorities. He also served as an active member of Acorda’s different committees responsible for ensuring medical governance as well as evaluating key in-licensing opportunities.

Dr. Rabinowicz received his medical degree from the Universidad Del Salvador, Buenos Aires, Argentina. He completed his residency in neurology at the University of Buenos Aires and his fellowship in Epilepsy and Neurophysiology at the University of Southern California, Los Angeles. Dr. Rabinowicz is Board Certified in Neurology and, for several years, served as both an Assistant Professor of Neurology and the Co-Director of the USC Comprehensive Epilepsy program, a selected NINDS site for antiepileptic drug development. Subsequently, Dr. Rabinowicz helped establish the Comprehensive Epilepsy Program at the Fleni Neurological Institute in Buenos Aires, Argentina. This program has become an international referral center for patients with refractory epilepsy as well as a leading institution for the clinical development of antiepileptic drugs. Dr. Rabinowicz has received several national and international awards for his research, is a Fellow of the American Academy of Neurology, and has published over 75 peer reviewed papers and several book chapters.

Leandra Mollanazar

Leandra Mollanazar joined SCI in December 2016 as Senior Vice President and General Manager.  Ms. Mollanazar has more than twenty-five years in the pharmaceutical and medical device industries in various executive leadership and global quality operation roles.  Ms. Mollanazar has broad and extensive expertise in varying pharmaceutical and medical technologies and industry standards including sterilization methods, finished product packaging configurations and supply chain tools as well as management of Research and Development, Clinical Trials and Commercial arenas. In addition, Ms. Mollanazar has extensive Global Regulatory Compliance experience with US, EU and other regulatory authorities throughout the world.

Prior to joining SCI, Ms. Mollanazar was with Catalent Pharma Solutions for more than thirteen years with her most recent role as Vice President of Quality Operations for Softgel technologies spanning eleven global manufacturing sites in the US, EU, Latin America and Asia Pacific.  Catalent is a global leader in development solutions and advanced drug delivery technologies, including softgels, for drugs, biologics, and consumer health care products.  Prior to joining Catalent, Ms. Mollanazar’s career crossed varying leadership operational and quality roles at Bausch & Lomb in aseptic manufacturing, analytical testing, packaging and distribution of ophthalmic, otic, inhalation and topical drug products. She also spent time at Johnson and Johnson where they manufactured vascular access and patient monitoring medical devices for global markets.

Ms. Mollanazar has a Bachelor’s of Science in Chemistry from University of Tampa, in Tampa, Florida.

Thorsteinn Thorsteinsson, Ph.D.

Thorsteinn_Thorsteinsson

Thorsteinn Thorsteinsson, Ph.D., joined us in September 2012. Prior to joining us, Dr. Thorsteinsson served from May 2011 to September 2012 as Group Leader and from September 2009 to May 2011 as Formulation Scientist at Banner Pharmacaps, the second largest pharmaceutical soft gelatin capsule manufacturer in the United States. At Banner, Dr. Thorsteinsson led a research and development group responsible for developing OTC and Rx soft gelatin capsules and chewable soft gelatin capsules for clinical studies and commercialization. Previously Dr. Thorsteinsson served as Senior Research Scientist at TransTech Pharma from March 2007 to September 2009, and served at deCODE Genetics as Senior Research Scientist from August 2003 to March 2007 and Researcher from August 1999 to August 2003. Dr. Thorsteinsson earned a PhD in Medicinal Chemistry and Pharmaceutical Research at University of Iceland.

Victoria Koller

Victoria Koller joined us in November 2015. Prior to joining us, Mrs. Koller spent over 20 years as a Quality leader at several biotechnology and pharmaceutical companies including Biogen Idec, Sandoz, Endo Qualitest, and Nexgen Pharma. She has expertise in regulatory inspection management and in the development and implementation of sustainable and compliant Quality Systems. In Mrs. Koller’s most recent role she led the Quality organization as the Vice President of Quality at Nexgen Pharma leading the Quality Assurance and Quality Control teams across three sites. Mrs. Koller earned a Bachelor of Science degree from California State University at Long Beach.

Dr. Ahmed Daak, Ph.D., MSc, MBBS

Dr. Ahmed Daak, Ph.D., MSc, MBBS, joined us in July 2015 as our Clinical Research Director/ Medical Director. Dr Daak has a Bachelor degree in Medicine, Bachelor degree in Surgery (MD), Masters in Medical Biochemistry, in addition he has a Ph.D. on Biomedical Science from London. Before joining SCI Dr. Daak was working at Harvard School of Public Health (HSPH), Harvard University, USA as Tekemi Research Fellow. His work at Harvard involves studying the genetic epidemiology of sickle cell disease, (SCD), modifiers of the disease severity, socio-economic impact of the disease and development of workable models for comprehensive preventive and management program for the disease. Dr Daak also worked as post-doctoral Research Fellow at the Lipidomics and Nutrition Research Center, London and was an Assistant Professor of Medical Biochemistry, Faculty of Medicine, at the University of Khartoum, Sudan.

Dr. Daak’s research work has expanded the knowledge about the role that bioactive lipids can play in the treatment and symptom amelioration of sickle cell disease (SCD), a devastating disease affecting more that 45 million patients worldwide, mainly children. The importance of Dr. Daak’s research is it provides evidence that treating patients with a special composition of omega-3 fatty acids might be a safe, effective and affordable approach to prevent the disease’s acute and chronic complications. Dr. Daak designed and conducted a very successful clinical trial that showed the efficacy of omega-3 treatment for patients with SCD. He has followed up this work with other laboratory studies to identify biochemical and molecular effects of omega-3 fatty acids on patients with SCD. This work by Dr. Daak, is regarded as a watershed contribution to the field of medicine.

In addition to his work on SCD, Dr. Daak conducted several clinical trials that investigated the role of omega-3 fatty acids on drug-resistant epilepsy and Fetal Brain development.

Dr. Daak is an active member in the International Society of Fatty Acids and Lipids (ISSFAL). Based on his groundbreaking research in the field, he was granted the New Investigator Award of 2014 at Stockholm.

Sancilio & Company, Inc.
Google+   Likedin